Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 3/2018

01-09-2018 | Clinical Study

G6PD as a predictive marker for glioma risk, prognosis and chemosensitivity

Authors: Chin-An Yang, Hsi-Yuan Huang, Cheng-Li Lin, Jan-Gowth Chang

Published in: Journal of Neuro-Oncology | Issue 3/2018

Login to get access

Abstract

Purpose

Glucose-6-phosphate dehydrogenase (G6PD) is a key enzyme preventing cells from oxidative damage and has been reported to have tumor-promoting roles. This study aims to comprehensively evaluate the predictive values of G6PD on brain tumor risk, prognosis and chemo-resistance.

Methods

A retrospective 13-year cohort study analyzing cancer risk using the Taiwan National Health Insurance Research Database (4066 G6PD deficiency patients and 16,264 controls) was conducted. Furthermore, RNAseq and clinical data of grade II–III glioma (LGG, n = 515) and glioblastoma (GBM, n = 155) were downloaded from The Cancer Genome Atlas (TCGA) and analyzed. Bioinformatics methods were applied to build a glioma prognostication model and to predict response to chemotherapy based on tumor G6PD-related gene expressions. The predicted results were validated in another glioma cohort GSE 16011 and in KALS1 cell line.

Results

G6PD-dificient patients were found to have an increased risk for cancers, especially for brain tumor (adjusted hazard ratio (HR) 10.5, 95% CI 1.03–7.60). Furthermore, higher tumor G6PD expression was associated with poor patient survival in LGG, but not in GBM. A prognostication model using expression levels of G6PD and 9 related genes (PSMA2, PSMB8, SHFM1, GSS, GSTK1, MGST2, POLD3, MSH2, MSH6) could independently predict LGG patient survival. Boosted decision tree analysis on 213 cancer cell line database revealed predictive values of G6PD expression on response to gemcitabine and bortezomib. Knockdown of G6PD in KALS1 cell line enhanced its sensitivity to both chemotherapeutic agents.

Conclusions

Our study suggests that G6PD could be a marker predicting glioma risk, prognosis and chemo-sensitivity.
Appendix
Available only for authorised users
Literature
1.
2.
Jeng W, Loniewska MM, Wells PG (2013) Brain glucose-6-phosphate dehydrogenase protects against endogenous oxidative DNA damage and neurodegeneration in aged mice. ACS Chem Neurosci 4(7):1123–1132CrossRefPubMedPubMedCentral
3.
Mejias R, Villadiego J, Pintado CO, Vime PJ, Gao L, Toledo-Aral JJ, Echevarria M, Lopez-Barneo J (2006) Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice. J Neurosci 26(17):4500–4508CrossRefPubMed
4.
Ramao A, Gimenez M, Laure HJ, Izumi C, Vida RC, Oba-Shinjo S, Marie SK, Rosa JC (2012) Changes in the expression of proteins associated with aerobic glycolysis and cell migration are involved in tumorigenic ability of two glioma cell lines. Proteome Sci 10(1):53CrossRefPubMedPubMedCentral
5.
6.
Dore MP, Davoli A, Longo N, Marras G, Pes GM. Glucose-6-phosphate dehydrogenase deficiency and risk of colorectal cancer in Northern Sardinia: A retrospective observational study. Medicine (Baltimore) 2016;95(44):e5254CrossRef
7.
Chien YH, Lee NC, Wu ST, Liou JJ, Chen HC, Hwu WL (2008) Changes in incidence and sex ratio of glucose-6-phosphate dehydrogenase deficiency by population drift in Taiwan. Southeast Asian J Trop Med Public Health 39(1):154–161PubMed
8.
Rinaldi M, Caffo M, Minutoli L, Marini H, Abbritti RV, Squadrito F, Trichilo V, Valenti A, Barresi V, Altavilla D, Passalacqua M, and Caruso G. ROS and brain gliomas: an overview of potential and innovative therapeutic strategies. Int J Mol Sci. 2016;17(6)
9.
10.
Zhang C, Zhang Z, Zhu Y, Qin S (2014) Glucose-6-phosphate dehydrogenase: a biomarker and potential therapeutic target for cancer. Anticancer Agents Med Chem 14(2):280–289CrossRefPubMed
11.
Furuta E, Okuda H, Kobayashi A, Watabe K (2010) Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 1805(2):141–152PubMedPubMedCentral
12.
Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, Group EGW (2014) High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii93-101CrossRefPubMed
13.
14.
Fack F, Tardito S, Hochart G, Oudin A, Zheng L, Fritah S, Golebiewska A, Nazarov PV, Bernard A, Hau AC, Keunen O, Leenders W, Lund-Johansen M, Stauber J, Gottlieb E, Bjerkvig R, Niclou SP (2017) Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways. EMBO Mol Med 9(12):1681–1695CrossRefPubMedPubMedCentral
15.
Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quinones-Hinojosa A (2010) Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 112(1):10–17CrossRefPubMed
16.
17.
Kim MM, Camelo-Piragua S, Schipper M, Tao Y, Normolle D, Junck L, Mammoser A, Betz BL, Cao Y, Kim CJ, Heth J, Sagher O, Lawrence TS, Tsien CI (2016) Gemcitabine plus radiation therapy for high-grade glioma: long-term results of a phase 1 dose-escalation study. Int J Radiat Oncol Biol Phys 94(2):305–311CrossRefPubMed
18.
Ahmad F, Dixit D, Sharma V, Kumar A, Joshi SD, Sarkar C, Sen E (2016) Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma. Cell Death Dis 7:e2213CrossRefPubMedPubMedCentral
19.
Ius T, Ciani Y, Ruaro ME, Isola M, Sorrentino M, Bulfoni M, Candotti V, Correcig C, Bourkoula E, Manini I, Pegolo E, Mangoni D, Marzinotto S, Radovic S, Toffoletto B, Caponnetto F, Zanello A, Mariuzzi L, Di Loreto C, Beltrami AP, Piazza S, Skrap M, and Cesselli D. A NF-kappaB signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells. Neuro Oncol 2017
20.
Lin JN, Lin CL, Lin MC, Lai CH, Lin HH, Yang CH, Sung FC, Kao CH (2015) Risk of leukaemia in children infected with enterovirus: a nationwide, retrospective, population-based, Taiwanese-registry, cohort study. Lancet Oncol 16(13):1335–1343CrossRefPubMed
21.
Lin JN, Lin CL, Yang CH, Lin MC, Lai CH, Lin HH, Kao CH (2016) Risk of Nephrotic Syndrome following Enteroviral Infection in Children: A Nationwide Retrospective Cohort Study. PLoS ONE 11(8):e0161004CrossRefPubMedPubMedCentral
22.
Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C (2012) Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 7(12):e51862CrossRefPubMedPubMedCentral
23.
Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Goncalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, Heyn H, Deng X, Egan RK, Liu Q, Mironenko T, Mitropoulos X, Richardson L, Wang J, Zhang T, Moran S, Sayols S, Soleimani M, Tamborero D, Lopez-Bigas N, Ross-Macdonald P, Esteller M, Gray NS, Haber DA, Stratton MR, Benes CH, Wessels LFA, Saez-Rodriguez J, McDermott U, Garnett MJ. A landscape of pharmacogenomic interactions in cancer. Cell 2016;166(3):740–754CrossRefPubMedPubMedCentral
24.
Felix K, Rockwood LD, Pretsch W, Nair J, Bartsch H, Bornkamm GW, Janz S (2002) Moderate G6PD deficiency increases mutation rates in the brain of mice. Free Radic Biol Med 32(7):663–673CrossRefPubMed
25.
Beaconsfield P, Rainsbury R, Kalton G (1965) Glucose-6-phosphate dehydrogenase deficiency and the incidence of cancer. Oncology 19:11–19CrossRef
26.
Chen J, Pitmon E, Wang K (2017) Microbiome, inflammation and colorectal cancer. Semin Immunol 32:43–53CrossRefPubMed
27.
Yang Z, Shen Y, Oishi H, Matteson EL, Tian L, Goronzy JJ, Weyand CM (2016) Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis. Sci Transl Med 8(331):331ra338CrossRef
28.
Savina NV, Nikitchenko NV, Kuzhir TD, Rolevich AI, Krasny SA, Goncharova RI (2016) The cellular response to oxidatively induced DNA damage and polymorphism of some DNA repair genes associated with clinicopathological features of bladder cancer. Oxid Med Cell Longev 2016:5710403CrossRefPubMed
29.
Chwastek J, Jantas D, Lason W (2017) The ATM kinase inhibitor KU-55933 provides neuroprotection against hydrogen peroxide-induced cell damage via a gammaH2AX/p-p53/caspase-3-independent mechanism: Inhibition of calpain and cathepsin D. Int J Biochem Cell Biol 87:38–53CrossRefPubMed
30.
Wilson A, Yakovlev VA (2016) Cells redox environment modulates BRCA1 expression and DNA homologous recombination repair. Free Radic Biol Med 101:190–201CrossRefPubMed
31.
Shahid M, Cho KM, Nguyen MN, Choi TG, Jo YH, Aryal SN, Yoo JY, Yun HR, Lee JW, Eun YG, Lee JS, Kang I, Ha J, Yoon HJ, Kim SY, Kim SS (2016) Prognostic value and their clinical implication of 89-gene signature in glioma. Oncotarget 7(32):51237–51250CrossRefPubMedPubMedCentral
32.
Wang ZL, Zhang CB, Cai JQ, Li QB, Wang Z, Jiang T (2015) Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II–IV gliomas. J Exp Clin Cancer Res 34:127CrossRefPubMedPubMedCentral
33.
Ju HQ, Lu YX, Wu QN, Liu J, Zeng ZL, Mo HY, Chen Y, Tian T, Wang Y, Kang TB, Xie D, Zeng MS, Huang P, Xu RH (2017) Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer. Oncogene 36(45):6282–6292CrossRefPubMedPubMedCentral
34.
Wang Z, Liang S, Lian X, Liu L, Zhao S, Xuan Q, Guo L, Liu H, Yang Y, Dong T, Liu Y, Liu Z, Zhang Q (2015) Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis. Sci Rep 5:9301CrossRefPubMedPubMedCentral
35.
Yin X, Tang B, Li JH, Wang Y, Zhang L, Xie XY, Zhang BH, Qiu SJ, Wu WZ, Ren ZG (2017) ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway. J Exp Clin Cancer Res 36(1):166CrossRefPubMedPubMedCentral
36.
Huang Y, Bell LN, Okamura J, Kim MS, Mohney RP, Guerrero-Preston R, Ratovitski EA (2012) Phospho-DeltaNp63alpha/SREBF1 protein interactions: bridging cell metabolism and cisplatin chemoresistance. Cell Cycle 11(20):3810–3827CrossRefPubMedPubMedCentral
37.
Fack F, Espedal H, Keunen O, Golebiewska A, Obad N, Harter PN, Mittelbronn M, Bahr O, Weyerbrock A, Stuhr L, Miletic H, Sakariassen PO, Stieber D, Rygh CB, Lund-Johansen M, Zheng L, Gottlieb E, Niclou SP, Bjerkvig R (2015) Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol 129(1):115–131CrossRefPubMed
38.
Mani A, Gelmann EP (2005) The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23(21):4776–4789CrossRefPubMed
39.
Odia Y, Kreisl TN, Aregawi D, Innis EK, Fine HA (2015) A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas. J Neurooncol 125(1):191–195CrossRefPubMed
40.
Raizer JJ, Chandler JP, Ferrarese R, Grimm SA, Levy RM, Muro K, Rosenow J, Helenowski I, Rademaker A, Paton M, Bredel M (2016) A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. J Neurooncol 129(1):139–146CrossRefPubMed
41.
Veldhuijzen van Zanten SEM, El-Khouly FE, Jansen MHA, Bakker DP, Sanchez Aliaga E, Haasbeek CJA, Wolf NI, Zwaan CM, Vandertop WP, van Vuurden DG, Kaspers GJL (2017) A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol 135(2):307–315CrossRef
Metadata
Title
G6PD as a predictive marker for glioma risk, prognosis and chemosensitivity
Authors
Chin-An Yang
Hsi-Yuan Huang
Cheng-Li Lin
Jan-Gowth Chang
Publication date
01-09-2018
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-018-2911-8

Other articles of this Issue 3/2018

Journal of Neuro-Oncology 3/2018 Go to the issue

Clinical Study

Fluorescein sodium-guided biopsy or resection in primary central nervous system lymphomas with contrast-enhancing lesion in MRI

Letter to the Editor

Widespread disseminated osseous metastases of intracranial meningioma with over 27-year-survivorship: a unique, idiosyncratic case

Topic Review

The utility of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with low-grade central nervous system (CNS) tumours: a systematic review

Letter to the Editor

Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy

Clinical Study

Rethinking medulloblastoma from a targeted therapeutics perspective

Clinical Study

18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy